HUTCHMED Highlights Clinical Data to be Presented at the 2026 ASCO Annual Meeting

Rhea-AI Summary

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) will present new and updated clinical data at the 2026 ASCO Annual Meeting (May 29–June 2, Chicago). Key results include a pivotal Phase II savolitinib study in MET-amplified gastric/GEJ cancer that met its primary ORR endpoint.

The Independent Review Committee–assessed ORR was 32.3% (95% CI: 21.2–45.1), with DCR 63.1%, median TTR 1.4 months, DoR 9.7 months and PFS 4.0 months. These data supported a China NDA that received priority review in December 2025. Multiple fruquintinib and surufatinib studies will also be presented.

News Market Reaction – HCM

-0.42%

-0.42% Session close to close

In the May 22 session, HCM declined 0.42%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement spotlights detailed Phase II savolitinib results, including an IRC‑assessed ORR of...

Analysis

This announcement spotlights detailed Phase II savolitinib results, including an IRC‑assessed ORR of 32.3% and DCR of 63.1%, which supported an NDA granted priority review in China. Multiple fruquintinib and surufatinib studies across tumor types reinforce a broad oncology strategy. Historical clinical news has produced mostly modestly positive moves, so investors may focus on upcoming ASCO presentations, regulatory decisions, and additional late‑stage readouts to gauge longer‑term impact.

Key Figures

ORR: 32.3% (95% CI: 21.2%, 45.1%) Disease control rate: 63.1% Median time to response: 1.4 months +5 more

8 metrics

ORR 32.3% (95% CI: 21.2%, 45.1%) IRC-assessed ORR in savolitinib Phase II gastric/GEJ study as of Oct 8, 2025

Disease control rate 63.1% IRC-assessed DCR in savolitinib Phase II gastric/GEJ study

Median time to response 1.4 months TTR in savolitinib Phase II gastric/GEJ study

Median duration of response 9.7 months (95% CI: 3.7, 18.5) DoR in savolitinib Phase II gastric/GEJ study

Median PFS 4.0 months (95% CI: 2.6, 5.0) Progression-free survival in savolitinib Phase II gastric/GEJ study

Data cut-off date October 8, 2025 Cut-off for savolitinib Phase II efficacy analysis

ASCO 2026 dates May 29–June 2, 2026 Timing of ASCO Annual Meeting where data will be presented

Efficacy threshold exceeded Primary ORR endpoint met Savolitinib Phase II ORR exceeded pre-specified efficacy threshold

Previous Clinical trial Reports

5 past events · Latest: Mar 22 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 22	Phase III initiation	Positive	+0.4%	Started Phase III HMPL-760 trial in relapsed/refractory DLBCL with ~240 patients planned.
Jan 13	Lancet SACHI data	Positive	+2.3%	Publication of Phase III SACHI savolitinib+osimertinib results confirming MET inhibition efficacy.
Jan 06	ESLIM-02 topline	Positive	+6.6%	Phase III ESLIM-02 sovleplenib trial met durable hemoglobin response primary endpoint in wAIHA.
Jan 04	Surufatinib Phase III	Positive	-2.0%	Initiated Phase III pancreatic trial after Phase II showed improved PFS, ORR and DCR vs control.
Dec 16	HMPL-A251 first-in-human	Positive	+0.5%	Began global Phase I/IIa development of HER2-targeted ATTC candidate HMPL-A251 in solid tumors.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Clinical milestones have usually produced modest positive moves, with one notable negative divergence on a strong combo-data update.

Recent Company History

Over the past six months, HUTCHMED has repeatedly advanced its pipeline, with multiple Phase III initiations, positive topline results, and a high‑profile SACHI publication in The Lancet. These events typically led to modest single‑day gains, except for one decline after strong pancreatic cancer combo data. Today’s ASCO‑focused savolitinib and fruquintinib update fits this pattern of steadily building a multi‑asset oncology portfolio through late‑stage and combination trials.

Key Terms

objective response rate, recist 1.1, independent review committee, disease control rate, +4 more

8 terms

objective response rate medical

"The study met its primary endpoint of objective response rate (“ORR”) per RECIST 1.1"

The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.

recist 1.1 medical

"primary endpoint of objective response rate (“ORR”) per RECIST 1.1, as assessed"

RECIST 1.1 is a standardized set of rules used in cancer clinical trials to measure how solid tumors respond to treatment by tracking changes in size on medical scans. Think of it as a consistent ruler and scorecard that tells doctors and regulators whether a drug is shrinking tumors, keeping them stable, or allowing them to grow. Investors care because RECIST-based results are common primary endpoints that influence regulatory decisions, trial success, and a therapy’s commercial prospects.

independent review committee medical

"per RECIST 1.1, as assessed by the Independent Review Committee (“IRC”)."

A group of independent experts who review proposed transactions, conflicts, or important decisions to ensure they are fair, compliant and in the best interest of shareholders. Think of them as an impartial referee or neighborhood oversight panel: they provide an outside check that reduces the risk of biased deals, increases transparency, and helps investors trust that management’s actions won’t unfairly benefit insiders or hidden parties.

disease control rate medical

"Secondary endpoints included the IRC-assessed disease control rate (DCR) of 63.1%"

The disease control rate is the share of patients in a clinical trial whose cancer or condition either shrinks or stops getting worse for a specified period after treatment. Think of it like the percentage of people for whom a treatment hits pause or nudges back the problem rather than letting it progress; higher rates suggest the therapy can meaningfully limit disease, which matters to investors assessing a drug’s potential efficacy and commercial value.

progression-free survival medical

"and median progression-free survival (PFS) of 4.0 (95%CI: 2.6, 5.0) months"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

new drug application regulatory

"The data supported the New Drug Application (NDA) submission to the China NMPA"

A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

priority review regulatory

"which was accepted and granted priority review in December 2025."

Priority review is a regulatory fast-track that shortens the time an agency spends evaluating a drug, vaccine or medical device application so a decision comes sooner than normal. For investors, it matters because a faster review is like an express lane to market: it can speed revenue potential and reduce regulatory uncertainty, but it does not guarantee approval and still requires the product to meet safety and effectiveness standards.

phase ii medical

"Results from the pivotal Phase II registration study of savolitinib in gastric cancer"

Phase II is the mid-stage clinical trial where a potential drug or medical treatment is tested in a larger group of patients to see if it works and to help determine the best dose and common side effects. For investors, Phase II results matter because they give the first meaningful evidence about effectiveness and safety—like a road test that shows whether a product has real promise before a much bigger, costly final trial and potential regulatory approval.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HONG KONG and FLORHAM PARK, N.J., May 22, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place from May 29 to June 2, 2026 in Chicago, USA.

Results from the pivotal Phase II registration study of savolitinib in gastric cancer or gastroesophageal junction adenocarcinoma patients with MET amplification in China will be presented during a rapid oral session. The study met its primary endpoint of objective response rate (“ORR”) per RECIST 1.1, as assessed by the Independent Review Committee (“IRC”). As of the data cut-off of October 8, 2025, the IRC-assessed ORR was 32.3% (95%CI: 21.2%, 45.1%), exceeding the pre-specified efficacy threshold. Secondary endpoints included the IRC-assessed disease control rate (DCR) of 63.1%, median time to response (TTR) of 1.4 months, median duration of response (DoR) of 9.7 (95%CI: 3.7, 18.5) months, and median progression-free survival (PFS) of 4.0 (95%CI: 2.6, 5.0) months, respectively. The data supported the New Drug Application (NDA) submission to the China National Medical Products Administration (NMPA), which was accepted and granted priority review in December 2025.

Additionally, further analyses of the fruquintinib’s FRESCO, FRESCO-2, FRUSICA-1 and FRUSICA-2 studies, as well as investigator-initiated studies of fruquintinib and surufatinib spanning across a diverse range of potential tumor indications will be presented.

Details of the presentations, including links to available abstracts, are as follows:

Abstract title	Presenter / Lead Author	Presentation details
SPONSORED STUDIES
A phase 2 pivotal study of savolitinib in patients with MET-amplified gastric cancer or gastroesophageal junction adenocarcinomas	Zhi Peng, Beijing, China	4011 Rapid Oral Abstract Session: Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary Monday, June 1, 2026 1:15 PM CDT
Tumor shrinkage and depth of response with fruquintinib in patients with metastatic colorectal cancer: Results from FRESCO and FRESCO-2	Elena Elez, Barcelona, Spain	3555 Poster Session: Gastrointestinal Cancer – Colorectal and Anal
Efficacy of fruquintinib plus sintilimab versus axitinib or everolimus by scores of IMDC risk factors and PD-L1 expression at baseline in previously treated advanced renal cell carcinoma: A subgroup analysis of FRUSICA-2 study	Kaiwei Yang, Beijing, China	4531 Poster Session: Genitourinary Cancer – Kidney and Bladder
Efficacy with fruquintinib plus sintilimab versus axitinib or everolimus in advanced renal cell carcinoma: A post-hoc analysis from FRUSICA-2 trial by baseline tumor burden	Yuanyuan Qu, Shanghai, China	4533 Poster Session: Genitourinary Cancer – Kidney and Bladder
Association of Palmar-plantar erythrodysesthesia syndrome (PPES), hypothyroidism and clinical outcome in previously treated endometrial cancer (EMC) with pMMR status: A subgroup analysis of FRUSICA-1	Xiaotian Han, Shanghai, China	e17612 Publication Only: Gynecologic Cancer
INVESTIGATOR-INITIATED STUDIES
Efficacy and safety of fruquintinib combined with chemotherapy versus bevacizumab combined with chemotherapy as second-line treatment for metastatic colorectal cancer: A prospective, multicenter, randomized controlled trial	Jianmin Xu, Shanghai, China	LBA3563 Poster Session: Gastrointestinal Cancer – Colorectal and Anal
CONCEPT (combination of cetuximab plus fruquintinib treatment ± immunotherapy): A multicenter, randomized, open-label phase II trial in first-line pMMR RAS/BRAF wild-type unresectable metastatic colorectal cancer	Yue Liu, Hangzhou, China	TPS3680 Poster Session: Gastrointestinal Cancer – Colorectal and Anal
Fruquintinib in combination with tislelizumab vs trifluridine/tipiracil and bevacizumab in MSS mCRC without active liver metastases: The IKF-080/QUINTIS trial	Joseph Tintelnot, Hamburg, Germany	TPS3684 Poster Session: Gastrointestinal Cancer – Colorectal and Anal
A phase 2 study of fruquintinib combined with sintilimab and chidamide in refractory MSS metastatic colorectal cancer: Preliminary efficacy and safety	Chang Wang, Changchun, China	2631 Poster Session: Developmental Therapeutics – Immunotherapy
Fruquintinib plus FOLFIRI or mFOLFOX6 as second-line therapy for patients with RAS-mutant metastatic colorectal cancer (mCRC): A phase II, multicenter, open-label study	Yun Xu, Shanghai, China	3528 Poster Session: Gastrointestinal Cancer – Colorectal and Anal
A randomized phase II trial of fruquintinib plus capecitabine versus capecitabine alone as maintenance therapy following first-line chemotherapy in metastatic colorectal cancer (mCRC)	Wenhua Li, Shanghai, China	3534 Poster Session: Gastrointestinal Cancer – Colorectal and Anal
A phase II trial of fruquintinib combined with cadonilimab in refractory MSS/pMMR colorectal cancer with pulmonary metastases	Mengzhou Guo, Shanghai, China	3552 Poster Session: Gastrointestinal Cancer – Colorectal and Anal
Biomarker-driven assessment of immunochemotherapy with or without fruquintinib as first-line treatment for advanced gastric/GEJ adenocarcinoma: Initial clinical results and subgroup analysis from the MGC-FLORA study	Xiaodong Zhu, Shanghai, China	4063 Poster Session: Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary
Phase II study of utidelone plus fruquintinib for the treatment of platinum-resistant recurrent ovarian cancer (FRUTD trial)	Hao Wen, Shanghai, China	5579 Poster Session: Gynecologic Cancer
Fruquintinib alternating with bevacizumab plus capecitabine as maintenance therapy after first-line treatment in metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study	Wangjun Liao, Guangzhou, China	e15539 Publication Only: Gastrointestinal Cancer – Colorectal and Anal
Intermittent fruquintinib plus trifluridine/tipiracil in refractory metastatic colorectal cancer (mCRC): A single-center, single-arm phase II study	Yifu He/Jiayu Niu, Hefei, China	e15560 Publication Only: Gastrointestinal Cancer – Colorectal and Anal
Phase I study of liposomal irinotecan plus fruquintinib as third- or later-line therapy for metastatic colorectal cancer	Qian Li, Nanning, China	e15571 Publication Only: Gastrointestinal Cancer – Colorectal and Anal
Chidamide combined with serplulimab and regorafenib or fruquintinib as third-line therapy for advanced colorectal cancer (C-ooperate/SCOG-C001): A single-arm, exploratory, multicenter, phase 2 trial	Wei Li, Suzhou, China	e15583 Publication Only: Gastrointestinal Cancer – Colorectal and Anal
Real-world use of fruquintinib in refractory metastatic colorectal cancer in the United States	Vasu Bansal, Kansas City, US	e15713 Publication Only: Gastrointestinal Cancer – Colorectal and Anal
Fruquintinib in combination with sintilimab and CAPEOX as first-line treatment for advanced gastric/gastroesophageal junction adenocarcinoma: A single-arm, open-label, multicenter phase Ib/II study (FUNCTION)	Beibei Chen, Zhengzhou, China	e16033 Publication Only: Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary
Fruquintinib in combination with camrelizumab, paclitaxel liposome, and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Updated results from a single-arm, phase II study	Yanhong Gu, Nanjing, China	e16070 Publication Only: Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary
Updated results of surufatinib combined with gemcitabine and cisplatin and immune checkpoint inhibitor (ICI) for unresectable locally advanced or metastatic intrahepatic cholangiocarcinoma	Xuetao Shi/Jingtao Zhong, Jinan, China	4136 Poster Session: Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary
Surufatinib plus KN046 and chemotherapy as first-line treatment for advanced pancreatic ductal adenocarcinoma: Updated results and biomarker analysis from a phase 1b/2 trial	Wenquan Wang, Shanghai, China	4198 Poster Session: Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary
Surufatinib combined with toripalimab for the treatment of recurrent ovarian clear cell carcinoma: Update of a prospective single center, single-arm phase II clinical trial	Huijuan Yang, Shanghai, China	5586 Poster Session: Gynecologic Cancer
Surufatinib for advanced or metastatic chemotherapy-refractory thymic epithelial tumor: A single-arm, single-center, phase II study	Bei Xu, Shanghai, China	8119 Poster Session: Lung Cancer – Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Surufatinib combined with anti-PD-1/PD-L1 antibody in the second line or monotherapy in third line treatment of advanced hepatocellular carcinoma: A single-arm, open-label, multi-center phase II study	Fuxiang Zhou, Wuhan, China	e16172 Publication Only: Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary
Efficacy and safety of surufatinib combined with immune checkpoint inhibitors plus chemotherapy in patients with biliary tract cancers: A real-world study	Shasha Fan, Changsha, China	e16222 Publication Only: Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary
Osimertinib plus savolitinib in osimertinib-resistant non-small-cell lung cancer with low level gene copy number MET: A multi-center, open-label, and phase 2 study	Xiang Han, Qingdao, China	e20079 Publication Only: Lung Cancer – Non-Small Cell Local-Regional/ Small Cell/Other Thoracic Cancers

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including but not limited to its expectations regarding the therapeutic potential of fruquintinib, savolitinib and surufatinib, the further clinical development for fruquintinib, savolitinib and surufatinib, its expectations as to whether any studies on fruquintinib, savolitinib and surufatinib would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study’s inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of fruquintinib, savolitinib and surufatinib, including as combination therapies, to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential markets of fruquintinib, savolitinib and surufatinib for a targeted indication, and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com
Media Enquiries
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
Deutsche Numis	Joint Broker
Duncan Monteith / Ramin Naji	+44 20 7545 8000

FAQ

What ASCO 2026 presentations is HUTCHMED (HCM) highlighting?

HUTCHMED is highlighting new and updated data from multiple studies of savolitinib, fruquintinib and surufatinib at the 2026 ASCO Annual Meeting. According to HUTCHMED, these include sponsored and investigator-initiated trials across gastric, colorectal, renal, gynecologic, hepatobiliary and thoracic cancers.

What are the key Phase II savolitinib gastric cancer results HUTCHMED (HCM) will show at ASCO 2026?

The pivotal Phase II savolitinib study met its primary endpoint of objective response rate in MET-amplified gastric/GEJ adenocarcinoma. According to HUTCHMED, Independent Review Committee–assessed ORR was 32.3%, disease control rate 63.1%, median time to response 1.4 months, duration of response 9.7 months and progression-free survival 4.0 months.

How did savolitinib ASCO 2026 data support HUTCHMED (HCM) regulatory progress in China?

Savolitinib Phase II data in MET-amplified gastric/GEJ cancer supported a New Drug Application in China. According to HUTCHMED, the China NMPA accepted the NDA and granted priority review in December 2025, reflecting the relevance of the objective response and disease control outcomes.

Which fruquintinib studies from HUTCHMED (HCM) will be featured at the 2026 ASCO Meeting?

HUTCHMED-linked ASCO 2026 content includes FRESCO, FRESCO-2, FRUSICA-1 and FRUSICA-2 analyses and multiple investigator-initiated fruquintinib trials. According to HUTCHMED, these span metastatic colorectal cancer, renal cell carcinoma, gastric/GEJ adenocarcinoma, esophageal cancer and ovarian cancer in various combination regimens.

What surufatinib clinical data associated with HUTCHMED (HCM) will appear at ASCO 2026?

ASCO 2026 will include several studies using surufatinib in combination and monotherapy across difficult cancers. According to HUTCHMED, these cover intrahepatic cholangiocarcinoma, pancreatic ductal adenocarcinoma, ovarian clear cell carcinoma, thymic epithelial tumors, hepatocellular carcinoma and biliary tract cancers in phase I/II and real-world settings.

When and where is HUTCHMED’s savolitinib Phase II gastric cancer data presented at ASCO 2026?

Savolitinib Phase II gastric/GEJ cancer data will be presented in a rapid oral session on June 1, 2026. According to HUTCHMED, it appears in Abstract 4011 within the Gastrointestinal Cancer – Gastroesophageal, Pancreatic, and Hepatobiliary session at 1:15 PM CDT in Chicago.